Key result
Distal embolisation during primary angioplasty for STEMI was associated with significantly higher mortality (9.2% vs. 2.7%, HR 3.41; 95% CI 1.73-6.71; p<0.0001), independent of time-to-treatment.
Why the study?
Does distal embolisation worsen myocardial perfusion and survival in STEMI patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors, regardless of time-to-treatment?
Cohort (n=1,182)
Yes
Does distal embolisation worsen myocardial perfusion and survival in STEMI patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors, regardless of time-to-treatment?
Effect estimate: HR 3.41 (95% CI 1.73-6.71)
Absolute Event Rate: 9.2% vs 2.7%
p-value: p=<0.0001
Distal embolisation during primary angioplasty for STEMI is associated with impaired myocardial perfusion and increased mortality, regardless of the time from symptom onset to treatment.
Distal embolisation flags high-risk STEMI PCI cases independent of delay; leaves open whether prevention strategies improve survival.
AIMS: Considerable interest has been focused in recent years on the role of distal embolisation as a major determinant of impaired reperfusion after primary angioplasty for STEMI. The aim of the current study was to evaluate in a large cohort of STEMI patients undergoing primary angioplasty with glycoprotein (Gp) IIb-IIIa inhibitors, whether the impact of distal embolisation on myocardial perfusion and survival may depend on time-to-treatment. METHODS AND RESULTS: Our population is represented by 1,182 patients undergoing primary angioplasty for STEMI included in the EGYPT database. Patients were grouped according to time-to-treatment (<3 hours, 3-6 hours, >6 hours). Distal embolisation was defined as an abrupt "cutoff" in the main vessel or one of the coronary branches of the infarct-related artery, distal to the angioplasty site. Myocardial perfusion was evaluated by angiography or ST-segment resolution, whereas infarct size was estimated by using peak creatine kinase (CK) and CK-MB. Follow-up data were collected between 30 days and one year after primary angioplasty. Distal embolisation was observed in 132 patients (11.1%) and tended to occur more frequently in late presenters (p=0.067). Patients with distal embolisation less often had post-procedural Thrombolysis In Myocardial Infarction (TIMI) 3 flow (p<0.001), post-procedural myocardial blush grade (MBG) 2-3 (p<0.001), complete ST-segment resolution (p=0.021) and larger infarct size (p=0.012). Distal embolisation was associated with a significantly higher mortality (9.2% vs. 2.7%, heart rate [HR] [95% CI]=3.41 [1.73-6.71], p<0.0001). The impact of distal embolisation on myocardial perfusion and survival persisted for all time intervals. CONCLUSIONS: This study showed that among STEMI patients treated with Gp IIb-IIIa inhibitors, the negative impact of distal embolisation on myocardial perfusion and mortality is independent of the time from symptom onset to balloon angioplasty.
No takes yet. Share an insight, caveat, or question.
Luca et al. (2012) conducted a cohort in STEMI (n=1,182). Distal embolisation vs. No distal embolisation was evaluated on Mortality (HR 3.41, 95% CI 1.73-6.71, p=<0.0001). Distal embolisation during primary angioplasty for STEMI was associated with significantly higher mortality (9.2% vs. 2.7%, HR 3.41; 95% CI 1.73-6.71; p<0.0001), independent of time-to-treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: